As federal lawmakers focus yet again on the costs of medications, yesterday, Eli Lilly announced it will be offering a generic version of their insulin, Humalog, at half-price.
In their news release, the company stated that the discounted insulin will be sold under the name Insulin Lispro and is the same molecule as Humalog.
David A. Ricks, Eli Lilly’s Chairman and Chief Executive Officer stated in the release "Solutions that lower the cost of insulin at the pharmacy have been introduced in recent months, but more people need help. We're eager to bring forward a low-priced rapid-acting insulin.”
“For people with diabetes, a lower-priced insulin can serve as a bridge that addresses gaps in the system until a more sustainable model is achieved." Ricks continued.
"While this change is a step in the right direction, all of us in the health care community must do more to fix the problem of high out-of-pocket costs for Americans living with chronic conditions," Ricks said. "We hope our announcement is a catalyst for positive change across the U.S. health care system."
According to Eli Lilly, Insulin Lispro will be available in pen and vial options. The price per vial will be $137.35 and a five-pack of KwikPens will be $265.20.
In a blog on the company's website, Ricks stated "While this change is a step in the right direction, all of us in the health care community must do more to fix the problem of high out-of-pocket costs for Americans living with chronic conditions."
Article Sponsored By